Zevra Therapeutics (ZVRA) Competitors $7.96 +0.11 (+1.40%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$7.98 +0.01 (+0.19%) As of 03/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. VERA, GLPG, KNSA, AAPG, IDYA, SDGR, IMCR, WVE, ANIP, and DYNShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Vera Therapeutics (VERA), Galapagos (GLPG), Kiniksa Pharmaceuticals (KNSA), Ascentage Pharma Group International (AAPG), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Immunocore (IMCR), Wave Life Sciences (WVE), ANI Pharmaceuticals (ANIP), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Vera Therapeutics Galapagos Kiniksa Pharmaceuticals Ascentage Pharma Group International IDEAYA Biosciences Schrödinger Immunocore Wave Life Sciences ANI Pharmaceuticals Dyne Therapeutics Vera Therapeutics (NASDAQ:VERA) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability. Which has higher valuation and earnings, VERA or ZVRA? Zevra Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$95.99M-$2.75-9.64Zevra Therapeutics$23.61M18.24-$46.05M-$2.24-3.55 Is VERA or ZVRA more profitable? Vera Therapeutics has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Vera Therapeutics' return on equity of -50.13% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -50.13% -39.50% Zevra Therapeutics -342.63%-159.54%-51.50% Which has more volatility & risk, VERA or ZVRA? Vera Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Does the MarketBeat Community favor VERA or ZVRA? Vera Therapeutics received 5 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 94.74% of users gave Zevra Therapeutics an outperform vote while only 66.13% of users gave Vera Therapeutics an outperform vote. CompanyUnderperformOutperformVera TherapeuticsOutperform Votes4166.13% Underperform Votes2133.87% Zevra TherapeuticsOutperform Votes3694.74% Underperform Votes25.26% Do insiders and institutionals hold more shares of VERA or ZVRA? 99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 21.7% of Vera Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate VERA or ZVRA? Vera Therapeutics presently has a consensus target price of $64.67, suggesting a potential upside of 143.84%. Zevra Therapeutics has a consensus target price of $22.29, suggesting a potential upside of 179.97%. Given Zevra Therapeutics' higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Vera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media refer more to VERA or ZVRA? In the previous week, Zevra Therapeutics had 3 more articles in the media than Vera Therapeutics. MarketBeat recorded 8 mentions for Zevra Therapeutics and 5 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.15 beat Zevra Therapeutics' score of 1.05 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Zevra Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryVera Therapeutics and Zevra Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$430.76M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-4.047.2023.1319.03Price / Sales18.24226.00383.8993.17Price / CashN/A65.6738.1634.64Price / Book4.656.476.944.33Net Income-$46.05M$141.90M$3.20B$247.06M7 Day Performance-0.62%-3.05%-2.32%-0.53%1 Month Performance2.18%-4.63%3.07%-3.74%1 Year Performance34.01%-8.61%11.16%1.72% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics3.0403 of 5 stars$7.96+1.4%$22.29+180.0%+34.0%$430.76M$23.61M-4.0420Positive NewsVERAVera Therapeutics3.1437 of 5 stars$27.08-2.2%$64.67+138.8%-39.5%$1.73BN/A-10.3840Positive NewsGLPGGalapagos0.7347 of 5 stars$25.82+0.4%$26.75+3.6%-22.6%$1.70B$275.65M0.001,123News CoveragePositive NewsKNSAKiniksa Pharmaceuticals3.0129 of 5 stars$23.36-1.9%$37.17+59.1%+16.9%$1.70B$423.24M-166.85220Positive NewsAAPGAscentage Pharma Group InternationalN/A$18.70-3.6%N/AN/A$1.63B$903.03M0.00600Analyst ForecastNews CoverageGap UpIDYAIDEAYA Biosciences3.5064 of 5 stars$18.39-0.3%$53.58+191.4%-59.8%$1.61B$7M-5.5780Positive NewsHigh Trading VolumeSDGRSchrödinger2.6282 of 5 stars$21.80-2.2%$32.29+48.1%-23.9%$1.59B$207.54M-9.32790Positive NewsGap UpIMCRImmunocore1.9541 of 5 stars$29.81-2.0%$65.64+120.2%-52.6%$1.49B$310.20M-31.38320Positive NewsWVEWave Life Sciences4.5879 of 5 stars$9.59-0.8%$22.60+135.7%+49.2%$1.47B$108.30M-8.64240Analyst ForecastNews CoverageANIPANI Pharmaceuticals3.8392 of 5 stars$64.26-0.1%$79.75+24.1%-1.9%$1.40B$614.38M-116.84600Positive NewsHigh Trading VolumeDYNDyne Therapeutics3.0497 of 5 stars$12.08-1.5%$47.46+292.9%-58.6%$1.37BN/A-3.39100 Remove Ads Related Companies and Tools Related Companies Vera Therapeutics Alternatives Galapagos Alternatives Kiniksa Pharmaceuticals Alternatives Ascentage Pharma Group International Alternatives IDEAYA Biosciences Alternatives Schrödinger Alternatives Immunocore Alternatives Wave Life Sciences Alternatives ANI Pharmaceuticals Alternatives Dyne Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZVRA Stock Free ZVRA Stock Alerts